Hemostemix Inc. (CVE:HEM) Director Peter Alan Lacey Sells 96,464 Shares

Hemostemix Inc. (CVE:HEM) Director Peter Alan Lacey sold 96,464 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of C$0.18, for a total value of C$16,881.20.

Hemostemix Stock Up 12.5 %

CVE HEM opened at C$0.18 on Friday. The stock’s 50-day moving average price is C$0.21 and its 200-day moving average price is C$0.12. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. Hemostemix Inc. has a 52 week low of C$0.04 and a 52 week high of C$0.43. The company has a market capitalization of C$26.23 million, a P/E ratio of -5.25 and a beta of 0.20.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.